Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro
- 30 November 1991
- journal article
- Published by Elsevier BV in European Journal of Cancer and Clinical Oncology
- Vol. 27 (11), 1423-1429
- https://doi.org/10.1016/0277-5379(91)90024-8
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Establishment and characterization of two new human ovarian cancer cell lines UWOV1 and UWOV2 and a subline UWOV2 (Sf) growing in serum-free conditions: Growth characteristics, biochemical, and cytogenetic studiesIn Vitro Cellular & Developmental Biology - Plant, 1990
- Phase I study and pharmacokinetics of intraperitoneal carboplatinCancer Treatment Reviews, 1985
- The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free mediumJournal of Immunological Methods, 1985
- Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.Journal of Clinical Oncology, 1985
- Low doses of interferon alpha result in more effective clinical natural killer cell activation.JCI Insight, 1985
- Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-αInternational Journal of Cancer, 1982
- Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferonInternational Journal of Cancer, 1980
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978
- Mechanism of the Antitumour Effect of Interferon in MiceNature, 1972
- Quantitative studies on viral interference in suspended L cellsVirology, 1962